Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Outcomes of posterior chamber collagen copolymer phakic intraocular lens with a central hole for moderate-to-high myopia

Poster Details

First Author: J.Ortiz Cazal SPAIN

Co Author(s):    S. Santamaria   N. Barba                 

Abstract Details


to evaluate the clinical outcomes of a posterior chamber phakic intraocular lens (pIOL) (Visian Implantable Collamer Lens V4c) for the correction of moderate to high myopia.


Grupo AdmiraVision-Hospital CIMA Sanitas-Universidad Autónoma de Barcelona


This study included the 10 consecutive eyes that had implantation of a new pIOL design with a central hole, at our department by the same surgeon. In patients unsuitable for laser vision corrección.The outcome measures that were evaluated included preoperative and postoperative uncorrected distant visual acuity (UDVA), best spectacle corrected distant visual acuity (CDVA), endothelial cell count (ECC), presence of lens opacification, intraocular pressure (IOP) and ICL vaulting The safety, efficacy, predictability, stability, and adverse events of the surgery were evaluated over 3 months.


The mean spherical equivalent decreased from −6.81 ± 1.11 diopters (D) preoperatively to −0.05 ± 0.27 D 3 months postoperatively; 96.8% of eyes were within ±0.50 D of the target and 100% of eyes were within ±1.00 D. All eyes had a decimal uncorrected distance visual acuity of 0.5 (20/40) or better at every follow-up visit. . Postoperatively, the intraocular pressure (IOP) remained stable over time. No significant rises in IOP (including pupillary block) and no secondary cataract were found. After 3 months, the mean vault was 505.2 ± 258.9 μm (range 280–690 μm), and the mean endothelial cell loss was 2.0%.


Implantation of the pIOL was safe, effective, predictable, and stable in the correction of moderate-to-high myopia even without peripheral iridectomy.

Financial Disclosure:


Back to Poster listing